November 29, 2011 (New York, New York) — The Angiovac endovascular clot removal system (Vortex Inc.) appears to be safe and effective for the treatment of massive pulmonary emboli and removal of large ...
LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...
(RTTNews) - Shares of medical technology firm AngioDynamics, Inc. (ANGO) are rising more than 8% in pre-market on Wednesday after the company said on Tuesday that the FDA granted Breakthrough Device ...
AngioDynamics, Inc. ANGO recently announced the safety and efficiency outcomes from the Registry of AngioVac System Procedures In Detail (“RAPID”) database. The study proved that the AngioVac System ...
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, ...
AngioDynamics (NASDAQ:ANGO) said that it has received breakthrough device designation from the FDA for its AngioVac System for the non-surgical removal of vegetation from the right heart. The ...
AngioDynamics, a provider of minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is to acquire all the outstanding capital stock of Vortex ...
Recently, AngioDynamics (ANGO) inked a definitive agreement to acquire the outstanding capital stock of privately-owned Vortex Medical Inc. for $15 million in cash. The acquisition is expected to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback